REHOVOT, Israel, July 20, 2017 -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the improvement of crop productivity and economics for food, feed and biofuel industries, announced today that it will release its financial results for the second quarter of 2017 on Thursday, August 10, 2017.
On the day of the announcement, the Company’s management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or +972-3-918-0644 internationally. Access to the call will also be available via live webcast through the Company’s website at www.evogene.com.
A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-254-7270 toll free from the United States, or +972-3-925-5940 internationally. The replay will be accessible through August 12, 2017, and an archive of the webcast will be available on the Company’s website through August 20, 2017.
About Evogene Ltd.:
Evogene (NASDAQ:EVGN) (TASE:EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key target markets: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at [email protected].
Forward Looking Statements:
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact: Alex Taskar Chief Financial Officer E: [email protected] T: (+972)-8-931-1963


UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Apple Turns 50: From Garage Startup to AI Crossroads 



